Pexmetinib (ARRY-614) is primarily investigated for its potential in cancer treatment, particularly in targeting specific pathways involved in tumor growth and survival. It functions as a dual inhibitor of Tie-2 and p38 MAPK, which are critical in angiogenesis and inflammation, both of which play significant roles in cancer progression. By inhibiting these pathways, Pexmetinib aims to disrupt the blood supply to tumors and reduce inflammation within the tumor microenvironment, potentially slowing down cancer growth and metastasis. Its application is being explored in various preclinical and clinical studies to assess its efficacy in treating solid tumors and hematologic malignancies. Additionally, its role in combination therapies with other anticancer agents is under investigation to enhance therapeutic outcomes and overcome drug resistance.